Alliance Pharma PLC Result of AGM (9931L)

TIDMAPH

RNS Number : 9931L

Alliance Pharma PLC

18 May 2022

 
 For immediate release   18 May 2022 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Result of AGM

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, at its Annual General Meeting held earlier today, all the resolutions, as set out in the Notice of Meeting, were duly passed on a poll.

The votes were as follows:

 
 RESOLUTION                      VOTES         %        VOTES        %       VOTES         % OF         VOTES WITHHELD 
                                  FOR                    AGAINST              TOTAL         ISC VOTED 
==============================  ============  =======  ===========  ======  ============  ===========  =============== 
 1    Report and Accounts        371,393,469   99.99    30,000       0.01    372,087,366   68.97        663,897 
 
 2    Final dividend             372,086,356   100.00   0            0.00    372,087,366   68.97        1,010 
 
 3    Re-elect P. Butterfield    371,812,794   99.94    238,118      0.06    372,087,366   68.97        36,454 
 
 4    Re-elect D. Cook           304,867,206   91.75    27,427,589   8.25    372,087,366   68.97        39,792,571 
 
 5    Re-elect A. Franklin       371,701,797   99.91    346,094      0.09    372,087,366   68.97        39,475 
 
 6    Re-elect R. Jones          318,832,469   94.70    17,845,835   5.30    372,087,366   68.97        35,409,062 
 
 7    Re-elect J. LeCouilliard   283,289,848   84.14    53,391,477   15.86   372,087,366   68.97        35,406,041 
 
 8    Elect K. Neirynck          371,168,677   99.76    882,235      0.24    372,087,366   68.97        36,454 
 
 9    Re-appoint Auditor         372,018,741   99.99    38,636       0.01    372,087,366   68.97        29,989 
 
      Remuneration 
 10    of Auditor                372,058,198   100.00   2,200        0.00    372,087,366   68.97        26,968 
 
 11   Allot shares               314,847,187   84.62    57,236,109   15.38   372,087,366   68.97        4,070 
 
      Disapply Pre-emption 
 12    rights                    318,400,733   85.57    53,682,363   14.43   372,087,366   68.97        4,270 
 

The number of the Group's shares in issue as at the date of the meeting was 539,461,338 ordinary shares of 1p each.

Please note that each share carries one vote and that a 'vote withheld' is not a vote in law and has not been counted in the calculation of the proportion of the votes for and against the resolution. Any proxy appointments which gave discretion to the Chairman have been included in the 'votes for' total.

Chris Chrysanthou

Head of Legal & Company Secretary

18 May 2022

For further information:

 
 Alliance Pharma plc                               + 44 (0)1249 466966 
 Cora McCallum, Head of Investor Relations 
  & Corporate Communications                       + 44 (0)1249 705168 
 [e-mail] 
 
 Buchanan                                         + 44 (0)20 7466 5000 
 Mark Court / Sophie Wills / Hannah Ratcliff 
 [e-mail] 
 
 Numis Securities Limited                         + 44 (0)20 7260 1000 
 Nominated Adviser: Freddie Barnfield / Duncan 
  Monteith 
 Corporate Broking: James Black 
 
 Investec Bank plc                                + 44 (0)20 7597 5970 
 Corporate Finance: Daniel Adams 
 Corporate Broking: Patrick Robb 
 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, Alliance employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBKFBQQBKDKPD

(END) Dow Jones Newswires

May 18, 2022 10:42 ET (14:42 GMT)